Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): A Dutch multicenter trial

Annals of Hematology

Volumn 73, Issue 5, 1996, Pages 247-252

  Kersten, M J ^a   Lange, R ^b,d   Smeets, M E P ^c   Vreugdenhil, G ^c,e   Roozendaal, K J ^b   Lameijer, W ^b   Goudsmit, R ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ST ANTONIUS HOSPITAL   (Netherlands)

^e ST JOSEPH HOSPITAL   (Netherlands)

Author keywords

Deferiprone; Hemosiderosis; Myelodysplastic syndrome; Thalassemia; Transfusion iron overload

Indexed keywords

CHELATING AGENT; DEFERIPRONE;

ADOLESCENT; ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; BLOOD TRANSFUSION; FEMALE; FERRITINS; HEMOSIDEROSIS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; PYRIDONES; TIME FACTORS; ZINC;

EID: 0029825581     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050236     Document Type: Article

References (25)

1. Cohen A (1987) Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1:521-544
2. Jaeger M, Aul C, Sohngen D, Germing U, Schneider W (1992) Iron overload in polytransfused patients with MDS - use of L1 for oral iron chelation. Abstract, 3rd Int. Conf. on oral chelators in the treatment of thalassemia and other diseases, Nice, 1992
3. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF (1981) Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304:319-324
4. Aul C, Gattermann N, Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358-362
5. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ (1994) Myelodysplastic Syndrome after autologous hone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83:3780-3786
6. Hoffbrand AV, Gorman A, Laulicht M, Garidi M, Economidou J, Georgipoulou P, Hussain MAM, Flynn DM (1979) Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet 1:947-949
7. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW (1991) Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr 118:540-545
8. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH (1986) Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. Lancet 1:869-873
9. Porter JB, Huehns ER, Hider RC (1989) The development of iron chelating drugs. Baillieres Clin Haematol 2:257-280
10. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV (1987) 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1:1294-1295
11. Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, Nortey P (1990) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 76:295-300
12. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ (1990) Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations. Br J Haematol 76:301-304
13. Töndury P, Kontoghiorghes GJ, Ridolfi-Lüthy A, Hirt A, Hoffbrand AV, Lottenbach AM, Sonderegger T, Wagner HP (1990) L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 76:550-553
14. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desal N, Puniyani RR, Chhablani AT (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion-dependent thalassaemia: Indian trial. Br J Haematol 82:460-466
15. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ (1992) Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypvrid-4-one (L1) in thalassemia major. Blood 80:593-599
16. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St. Louis P, Freedman HH, McClelland RA, Templeton DM (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 336:1275-1279
17. Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, McClelland RA, Templeton DM (1992) Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 79:2741-2748
18. Hoffbrand AV, Bartlett AN, Veys PA, O'Connor NTJ, Kontoghiorghes GJ (1989) Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet II:457-458
19. Al-Refaie FN, Wonke B, Hoffbrand AV (1994) Deferiprone-associated myelotoxicity. Eur J Haematol 53:298-301
20. Goudsmit R, Kersten MJ (1992) Long-term treatment of transfusion hemosiderosis with the oral iron chelator L1. Drugs of Today 28 [Suppl A]:133-135
21. Marsh JH, Hundert M, Schulman P (1990) Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 76:148-149
22. Jensen PD, Jensen IM, Ellegaard J (1992) Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 80:121-124
23. Kontoghiorghes GJ (1993) Update on the worldwide oral iron chelation therapy with L1-deferiprone. 4th Int. conf. on oral iron chelation in the treatment of thalassaemia and other diseases, Cyprus, 1993
24. Brock JH, Ng J (1983) The effect of desferrioxamine on the growth of Staphylococcus aureus, Yersinia enterocolitica and Streptococcus faecalis in human serum: uptake of DFO-bound iron. FEMS Microbiol Lett 20:439-443
25. Boelaert JR, van Roost GF, Vergauwe PL, Verbanck JJ, de Vroey C, Segaert MF (1988) The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 29:261-266